Clinical Trials Logo

Prostatic Neoplasms clinical trials

View clinical trials related to Prostatic Neoplasms.

Filter by:

NCT ID: NCT01341652 Completed - Prostate Cancer Clinical Trials

Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer

Start date: May 23, 2011
Phase: Phase 2
Study type: Interventional

The investigators are trying to find new methods to treat prostate cancer. The approach the investigators are taking is to try to enhance patients' own immune response against the cancer. In this study the investigators will be testing the effectiveness of a vaccine that may be able to help the body fight prostate cancer.

NCT ID: NCT01338831 Completed - Clinical trials for Metastatic Breast Cancer

Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

Start date: September 2011
Phase: Phase 1
Study type: Interventional

The purpose of this first multi-dose study in cancer patients is to determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D), characterize the safety, tolerability and pharmacokinetics profile. Once the MTD has been established and/or a RP2D chosen, the study will enroll patients into the expansion portion of the study.

NCT ID: NCT01338792 Completed - Clinical trials for Recurrent Prostate Cancer

Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer

Start date: June 2006
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well giving oxaliplatin and pemetrexed disodium together works in treating patients with refractory hormone-resistant prostate cancer. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving oxaliplatin together with pemetrexed disodium may kill more tumor cells.

NCT ID: NCT01337258 Completed - Cancer Clinical Trials

Economic Analyses of the REDUCE Trial

Start date: January 2010
Phase: N/A
Study type: Observational

The objective of this project is to conduct a retrospective economic analysis of the use of dutasteride for the prevention of prostate cancer based on data from the REDUCE clinical trial. REDUCE is a 4-year, phase 3, randomized, double-blind, parallel assignment clinical trial of the use of dutasteride compared with no chemopreventive treatment. The REDUCE trial was a four-year, international, multicenter, randomized, double-blind, placebo-controlled, parallel group study. There were 790 investigators in 42 countries.

NCT ID: NCT01331083 Completed - Prostate Cancer Clinical Trials

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Start date: September 9, 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether the new drug PX-866 will slow the growth of your prostate cancer. The investigators will also watch you carefully for any side effects that PX-866 might cause.

NCT ID: NCT01326286 Completed - Prostate Cancer Clinical Trials

Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) for Localized Prostate Cancer

CEASAR
Start date: March 2011
Phase:
Study type: Observational

This study will primarily compare the effectiveness of surgery and radiation for localized prostate cancer, the most common male cancer. It will focus on modern technologies and control for differences in patients and treatments that may affect both cancer-related and patient-reported outcomes (such as impotence and incontinence). By figuring out what treatments "work best, in which patients and in whose hands", it will help men with prostate cancer make better decisions regarding their care.

NCT ID: NCT01325311 Completed - Clinical trials for Prostate Adenocarcinoma

Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer

Start date: December 2011
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies cholecalciferol and genistein compared to placebo in treating patients with early stage prostate cancer. Cholecalciferol and genistein may slow the growth of cancer cells and may be an effective treatment for prostate cancer.

NCT ID: NCT01324583 Completed - Prostate Cancer Clinical Trials

Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer

Start date: January 2011
Phase: Phase 1
Study type: Interventional

Primary Objective: - To assess the tolerability at global doses Secondary Objectives: - Safety - Pharmacokinetics - Efficacy

NCT ID: NCT01322490 Completed - Clinical trials for Prostate Cancer Metastatic

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Prospect
Start date: November 28, 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether PROSTVAC alone or in combination with GM-CSF is effective in prolonging overall survival in men with few or no symptoms from metastatic, castrate-resistant prostate cancer.

NCT ID: NCT01320735 Completed - Prostate Cancer Clinical Trials

Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Leuprorelin (Lucrin Depot) in Patients With Advanced Prostate Cancer (PCa) in Russia

Start date: February 2011
Phase: N/A
Study type: Observational

The objective of this study was to describe treatment patterns of leuprorelin over 2 years using an intermittent, adjuvant regimen in participants with advanced prostate cancer (PCa)